



09/708475-20PC

LAW OFFICES OF  
**SYNNESTVEDT & LECHNER LLP**  
2600 ARAMARK TOWER  
1101 MARKET STREET  
PHILADELPHIA, PA 19107-2950  
TELEPHONE (215) 923-4466  
FACSIMILE (215) 923-2189  
E-MAIL [synnlech@synnlech.com](mailto:synnlech@synnlech.com)  
[www.synnlech.com](http://www.synnlech.com)  
February 22, 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.: RE39,265  
Issued: September 5, 2006  
Inventor: Joseph T. Strupczewski; Kenneth J. Bordeau; Edward J. Glamkowski; Yulin Chiang; Grover C. Helsley  
Title: HETEROARYLPIPERIDINES, AND THEIR USE AS ANTIPSYCHOTICS AND ANALGESICS  
Atty. Docket No.: P25,984-A REI

---

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence, together with any other document indicated as being enclosed, was deposited with the U.S. Post Office as first-class mail, postage prepaid, in an envelope addressed to: Office of Petitions, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on February 22, 2007.

February 22, 2007  
Date

Barbara G. Makariou

Office of Petitions  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**Petition Under 37 C.F.R. § 1.322(b)  
for Issuance of A Corrected Patent**

**Certificate**  
MAR 01 2007  
**of Correction**

Sir:

The patent owner petitions the Commissioner for issuance of a corrected patent for U.S. Patent No. RE39,265 in lieu of the issuance of a Certificate of Correction to correct printing errors, all of which are the result of Patent Office mistakes.

MAR - 2 2007

**Listing of Errors**



In column 6, line 36, the term “ $-\text{CH}_2-\text{C}=\text{CH}-\text{CH}_2-$ ” should read  
--  $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-$  --.

In column 9, line 11, the term “ $(\text{C}_1-\text{C})$ ” should read --  $(\text{C}_1-\text{C}_{12})$  --.

In column 9, line 66, the term “ $\text{CHR}_6$ ” should read --  $\text{CHR}_8$  --.

In column 13, line 44, the term “carboxylic” should read -- carbocyclic --.

In column 15, line 60, in the structure the subscript “i” should not appear, and a semicolon should appear after the chemical structure so that the structure



In column 19, line 9, the term “ $\text{CHR}_6$ ” should read --  $\text{CHR}_8$  --.

In column 22, line 67, a period should appear after the chemical structure.

In column 24, line 43, the term “ $\text{CHR}_6$ ” should read --  $\text{CHR}_8$  --.

MAR - 2 2007

In column 24, line 44, the phrase "R<sub>9</sub> is N-R<sub>9</sub>" should read -- R<sub>9</sub> in N-R<sub>9</sub> --.

In column 25, line 58, a comma should appear immediately after the term "I".

In column 34, line 4, the fragment "benzoxisoxazole" should read -- benzisoxazole --.

In column 35, line 63, the fragment "methoxtrphenyl" should read  
-- methoxyphenyl --.

In column 38, line 14, the term "Chlorpromaxine" should read -- Chlorpromazine --.

In column 39, line 34, a comma should appear in place of a period, so that the phrase  
"acid. Primogel," reads as -- acid, Primogel, --

In column 42, line 6, a comma should appear in place of a period, so that the term  
"1 h." reads -- 1 h, --.

In column 49, line 67, a comma should appear in place of a period, so that the term  
"1 h." reads -- 1 h, --.

In column 50, line 13, the number "58.74%" should read --58.47% --.

In column 51, line 22, the fragment "piperdiny" should read -- piperidinyl --.

In column 54, line 7, the fragment "piperdiny" should read -- piperidinyl --.

In column 54, line 26, subscripted value of fifty should be thirty, so that the fragment

MAR - 2 2007

“H<sub>50</sub>” reads -- H<sub>30</sub> --.

In column 55, line 65, the fragment “piperdinyI” should read -- piperidinyI --.

In column 56, line 39, the extra hyphen should be deleted.

In column 56, line 39, a period should appear in place in of a period, so that the number “3,4” reads as -- 3.4 --.

In column 56, line 44, the term “being” should read -- beige --.

In column 56, line 45, the term “recrystalized” should read -- recrystallized --.

In column 56, line 48, the term “Calcaulated” should read -- Calculated --.

In column 56, line 56, an additional comma should appear, so that the phrase “(1.5 g 0.0107 mol),” reads -- (1.5 g, 0.0107 mol), --.

In column 56, line 67, the term “addiitional” should read -- additional --.

In column 57, line 5, the term “Caculated” should read -- Calculated --.

In column 57, line 14, an additional comma should appear, so that the phrase “(1.5 g 0.0067 mol),” reads -- (1.5 g, 0.0067 mol), --.

In column 57, line 18, the term “mxiture” should read -- mixture --.

MAR - 2 2007.

In column 57, line 37, the term "volume" should read -- mixture --.

In column 57, line 38, the term "mg" should read -- g --.

In column 57, line 46, the term " $\text{SiO}_4$ " should read --  $\text{SiO}_2$  --.

In column 57, line 47, a period should appear in place of a comma, so that the term  
"1,1" reads -- 1.1 --.

In column 57, line 54, the term "61.5%" should read -- 6.15% --.

In column 57, line 46, the phrase "6.33% H" should read -- 6.33% N --.

In column 58, line 12, the term "acetnotrile" should read -- acetonitrile --.

In column 58, line 39, the term "methylate" should read -- methylene --.

In column 58, line 45, the phrase "80 mol" should read -- 80 ml --.

In column 59, line 9, a comma should appear in place of a period, so that the phrase  
"dichloromethane. 600 ml" reads -- dichloromethane, 600 ml --.

In column 59, line 34, the term "dicholormethane" should read -- dichloromethane --.

In column 59, line 61, a small letter el should appear in place of capital I, so that the  
term "HCI" reads -- HCl --.

MAR - 2 2007

In column 59, line 65, the term "recrystalize" should read -- recrystallize --.

In column 60, line 3, the term "hydrocyloride" should read -- hydrochloride --.

In column 60, line 3, a dash should appear in place of the second equal sign, so that the phrase "m.p.=139°=141° C." reads -- m.p.=139°–141° C. --

In column 60, line 4, a centerdot should appear in place of a comma, and a small letter el should appear in place of capital I, so that the fragment "O<sub>4</sub>,HCl" reads -- O<sub>4</sub>·HCl --.

In column 60, line 45, an additional comma should appear, so that the phrase "(3.7 g 0.0113 mol)" reads -- (3.7 g, 0.0113 mol) --.

In column 60, line 55, the fragment "benzisoxaol" should read -- benzisoxazol --.

In column 61, line 20, a centerdot should appear in place of a comma, and the superfluous digit 4 should not appear, so that the fragment "O<sub>2</sub>,0.5C<sub>4</sub>H<sub>4</sub>O<sub>4</sub>4" should read -- O<sub>2</sub>·0.5C<sub>4</sub>H<sub>4</sub>O<sub>4</sub>--.

In column 61, line 35, the term "concentrate" should read -- concentrated --.

In column 61, line 54, the term "i80" should read -- (80 --.

In column 61, line 61, the term "weighted" should read -- weighed --.

In column 62, line 7, a period should appear in place of a comma, so that the number

MAR - 2 2007

“1,4” reads -- 1.4 --.

In column 62, line 9, a comma should appear in place of a period, and an additional comma should appear, so that the phrase “(2.5 g 0.0103 mol). KI” reads -- (2.5 g, 0.0103 mol), KI --

In column 62, line 25, the term “9.88N” should read -- 9.88% N --.

In column 62, line 36, the term “dimethylformaide” should read -- dimethylformamide --.

In column 62, line 39, the term “dimethylformaide” should read -- dimethylformamide --.

In column 63, line 14, a comma should appear in place of a period, so that the phrase “mmoles). K<sub>2</sub>CO<sub>3</sub>” reads -- mmoles), K<sub>2</sub>CO<sub>3</sub> --.

In column 63, line 39, the term “inoluble” should read -- insoluble --.

In column 63, line 44, the term “weight” should read -- weighed --.

In column 63, line 64, the term “solified” should read -- solified --.

In column 64, line 2, the term “4.91H” should read -- 4.91% H --.

In column 64, line 17, a small letter el should appear in place of capital I, so that the term “HCl” reads -- HCl --.

MAR - 2 2007

In column 64, line 48, the term "dimethylforamide" should read  
-- dimethylformamide --.

In column 64, line 56, a comma should appear after "g", so that the phrase  
"(8.4 g 0.0485 mol)" reads -- (8.4 g, 0.0485 mol) --.

In column 65, line 2, the term "piperdinyI" should read -- piperidinyl --.

In column 65, line 26, the term "solvet" should read -- solvent --.

In column 65, line 44, a comma should appear after "g", so that the phrase  
"(2.5 g 0.022 mol)" reads -- (2.5 g, 0.022 mol) --.

In column 65, line 45, the term "miture" should read -- mixture --.

In column 65, line 53, a small letter el should appear in place of capital I, so that the  
term "HCl" reads -- HCl --.

In column 66, line 5, the number "0.0107" should read -- 0.107 --.

In column 66, line 21, a small letter el should appear in place of capital I, so that the  
formula " $C_{11}H_{13}ClO_4$ " reads --  $C_{11}H_{13}ClO_4$  --.

In column 67, line 10, the term "ANALSYS" should read -- ANALYSIS --.

In column 67, line 10, a small letter el should appear in place of capital I, so that the

MAR - 2 2007



formula "C<sub>11</sub>H<sub>13</sub>ClO<sub>3</sub>" reads -- C<sub>11</sub>H<sub>13</sub>ClO<sub>3</sub> --.

In column 67, line 29, a small letter el should appear in place of capital I, so that the formula "C<sub>11</sub>H<sub>15</sub>ClO<sub>3</sub>" reads -- C<sub>11</sub>H<sub>15</sub>ClO<sub>3</sub> --.

In column 67, line 47, a closed bracket symbol should appear in place of the close parenthesis symbol, so that the fragment "piperidinyl)propoxy]" reads -- piperidinyl)propoxy] --.

In column 67, line 51, the term "EXAMPE" should read -- EXAMPLE --.

In column 68, line 18, the term "basic" should read -- base --.

In column 68, line 19, a small letter el should appear in place of capital I, so that the term "HCl" reads -- HCl --.

In column 68, line 24, the term "Calcuated" should read -- Calculated --.

In column 68, line 24, a period should appear in place of a comma, and small letter el in place of capital letter el, so that the formula "C<sub>21</sub>H<sub>24</sub>FN<sub>3</sub>O<sub>2</sub>.2HCL" reads -- C<sub>21</sub>H<sub>24</sub>FN<sub>3</sub>O<sub>2</sub>.2HCl --.

In column 68, line 29, the superfluous fragment "propoxy]" should not appear.

In column 68, line 46, a small letter el should appear in place of capital I, so that the formula "C<sub>13</sub>H<sub>16</sub>ClNO<sub>3</sub>" reads -- C<sub>13</sub>H<sub>16</sub>ClNO<sub>3</sub> --.

MAR - 2 2007

In column 68, line 55, the term "aqueous" should read -- aqueous --.

In column 68, line 58, a small letter el should appear in place of capital I, so that the term "HCl" reads -- HCl --.

In column 69, line 32, the term "piperdinyI" should read -- piperidinyl --.

In column 69, line 46, a small letter el should appear in place of capital I, so that the term "HCl" reads -- HCl --.

In column 69, line 46, the term "recipitated" should read -- precipitated --.

In column 69, line 51, a period should appear in place of a comma, and small letter el in place of capital letter I, so that the formula " $C_{24}H_{29}FN_2O_3, HCl$ " reads --  $C_{24}H_{29}FN_2O_3, HCl$  --.

In column 69, line 56, the term "6Fluoro" should read -- 6-Fluoro --.

In column 69, line 67, the term "water/ic" should read -- water/ice --.

In column 70, line 2, the phrase "the concentrated" should read -- then concentrated --.

In column 70, line 7, the term "piperdinyI" should read -- piperidinyl --.

In column 70, line 47, a tilde should appear in place of the minus sign so that the term "(-18 g)" reads -- (~18 g) --.

MAR - 2 2007

In column 71, line 5, the formula "NaSO<sub>4</sub>" should read -- Na<sub>2</sub>SO<sub>4</sub> --.

In column 71, line 21, a tilde should appear in place of the minus sign so that the term  
"(-110° C.)" reads -- (~110° C.) --.

In column 71, line 32, a semicolon should appear in place of a colon, so that the term  
"g:" read -- g; --.

In column 71, line 56, the term "f" should read -- of --.

In column 71, line 59, a hyphen should appear immediately after numeral 1.

In column 71, line 62, a small letter el should appear in place of capital I, so that the  
term "HCl" reads -- HCl --.

In column 72, line 15, the term "solutio" should read -- solution --.

In column 72, line 21, the term "is" should read -- in --.

In column 72, line 36, a small letter el should appear in place of capital I, so that the  
formula "C<sub>12</sub>H<sub>16</sub>ClNO<sub>2</sub>" reads -- C<sub>12</sub>H<sub>16</sub>ClNO<sub>2</sub> --.

In column 72, line 58, the term "Calculate" should read -- Calculated --.

In column 73, line 1, the term "dimethylfomamide" should read  
-- dimethylformamide --.

MAR - 2 2007

In column 73, line 4, the term "dimethylformamdie" should read  
-- dimethylformamide --.

In column 73, line 6, the phrase "is twas" should read -- it was --.

In column 73, line 6, the phrase "in water" should read -- into water --.

In column 73, line 11, the term "sampe" should read -- sample --.

In column 73, line 14, the term "ethy" should read -- ethyl --.

In column 73, line 20, a small letter el should appear in place of capital I, so that the  
formula " $C_{12}H_{16}ClNO_3$ " reads --  $C_{12}H_{16}ClNO_3$  --.

In column 73, line 22, the fragment "yl)1" should read -- yl)-1--.

In column 73, line 30, a small letter el should appear in place of capital I, so that the  
term "HCl" reads -- HCl --.

In column 73, line 33, the term "Utilizing" should read -- utilizing --.

In column 73, line 55, the term "8.0" should read -- 8.0 g --.

In column 73, line 60, a small letter el should appear in place of capital I, so that the  
term "HCl" reads -- HCl --.

In column 74, line 1, a small letter el should appear in place of capital I, so that the

MAR - 2 2007

MAR - 2 2007

fragment "HCl" reads -- HCl --.

In column 74, line 18, the fragment "iperidiny" should read -- piperidiny --.

In column 74, line 20, a comma should appear in place of a period, so that the phrase  
"17.7 mmols)." reads -- 17.7 mmols), --.

In column 74, line 22, the term "(3g)" should read -- (3 g) --.

In column 74, line 27, the term "weight" should read -- weighed --.

In column 74, line 44, the term "16" should read -- 16 hours. The reaction was poured  
into water, and the mixture --.

In column 74, line 49, the term "wad" should read -- was --.

In column 74, line 55, the fragment "benzisoxazol" should read -- benzisoxazol --.

In column 74, line 55, the fragment "piperdiny" should read -- piperidiny --.

In column 75, line 4, the term "pressue" should read -- pressure --.

In column 75, line 9, the term "based" should read -- base --.

In column 75, line 32, the term "4.2 g" should read -- 4.2 g of --.

In column 75, lines 64 to 65, the term "triphenylphosphate" should read

MAR - 2 2007

-- triphenylphosphine --.

In column 76, line 5, a small letter el should appear in place of capital I, so that the term "HCl" reads -- HCl --.

In column 76, line 7, a small letter el should appear in place of capital I, so that the formula " $C_{25}H_{30}ClN_2O_3$ " reads --  $C_{25}H_{30}ClN_2O_3$  --.

In column 76, line 11, the fragment "1,2Benzisoxazol" should read -- 1,2-Benzisoxazol --.

In column 76, line 23, the phrase "20 m" should read -- 20 ml --.

In column 76, line 44, a small letter el should appear in place of capital I, so that the formula " $C_{13}H_{15}ClO_3$ " reads --  $C_{13}H_{15}ClO_3$  --.

In column 76, line 55, the term "acetontrile" should read -- acetonitrile --.

In column 77, line 20, a small letter el should appear in place of capital I, so that the term "HCl" reads -- HCl --.

In column 78, line 13, no period should appear after the term "HPLC".

In column 78, line 18, a small letter el should appear in place of capital I, so that the formula " $C_{12}H_{14}ClNO_2$ " reads --  $C_{12}H_{14}ClNO_2$  --.

In column 78, line 19, the number "6.89%" should read -- 5.89%--.

MAR - 2 2007.

MAR - 9 2007

In column 78, line 45, the term "dmethylformamide" should read  
-- dimethylformamide --.

In column 78, line 47, the term "hor" should read -- hour --.

In column 78, line 53, the term "concentratedf" should read -- concentrated --.

In column 78, line 54, the term "chormatography" should read -- chromatography --.

In column 78, line 57, a small letter el should appear in place of capital I, so that the  
formula "C<sub>11</sub>H<sub>12</sub>CINO" reads -- C<sub>11</sub>H<sub>12</sub>CINO --.

In column 78, line 63, the number "0.0107" should read -- 0.017 --.

In column 79, line 42, the term "T" should read -- To --.

In column 79, line 44, the term "tetrahydrofuan" should read -- tetrahydrofuran --.

In column 79, line 46, the term "tetrahydrofuan" should read -- tetrahydrofuran --.

In column 79, line 48, the phrase "and the" should read -- and then --.

In column 81, line 63, the fragment "benzisoxanol" should read -- benzisoxazol --.

In column 82, line 17, the phrase "concentrated from" should read -- concentrated to  
afford 21.9 g of a brown solid. The solid was recrystallized from --.

MAR - 2 2007

In column 82, line 23, the phrase "was stirred was heated" should read  
-- was stirred and heated --.

In column 82, line 62, the phrase "EXAMPLE 9" should read -- EXAMPLE 96 --.

In column 83, line 32, the fragment "benzisoxanol" should read -- benzisoxazol --.

In column 83, line 55, the fragment "benzisoxanol" should read -- benzisoxazol --.

In column 84, line 14, the fragment "O<sub>3</sub>" should read -- O --.

In column 84, line 23, the fragment "aminopropyl" should read -- aminobutyl --.

In column 84, line 42, the term "4thio" should read -- 4-thio --.

In column 85, line 14, a closed bracket symbol should appear after the closed  
parenthesis symbol, so that the fragment "methoxyphenyl)butylpiperidine"  
reads -- methoxyphenyl)]butylpiperidine --

In column 87, line 43, an opened parenthesis symbol should appear so that the  
fragment "phenylmethyl)" reads -- (phenylmethyl) --.

In column 87, line 53, an opened parenthesis symbol should appear so that the  
fragment "phenylmethyl)" reads -- (phenylmethyl) --.

In column 87, line 55, an opened parenthesis symbol should appear so that the



fragment "phenylmethyl)" reads -- (phenylmethyl) --.

In column 88, line 38, the extra digit and a hyphen should not appear so that the fragment "[4-[4-(4-bromo" reads -- [4-[(4-bromo --.

In column 90, line 18, a tilde should appear in place of the overline symbol so that the phrase " ~80 ml" reads -- ~80 ml --.

In column 90, line 54, a tilde should appear in place of the minus sign so that the phrase "(-7.1 gm)" reads -- (~7.1 gm) --.

In column 91, line 62, a tilde should appear in place of the overline symbol so that the phrase "( ~5 ml)" reads -- (~5 ml) --.

In column 91, line 64, a tilde should appear in place the overline symbol, and the number should not be superscripted, so that the term "--<sup>10</sup>" reads -- ~10 --.

In column 92, line 35, an closed bracket symbol should appear in place of the first closed parentheses symbol so that the fragment "piperidiny]propanol" reads -- piperidiny]propanol --.

In column 92, line 64, a tilde should appear in place of the overline symbol so that the phrase "( ~5 ml)" reads -- (~5 ml) --.

In column 93, line 59, a tilde should appear in place of the overline symbol so that the phrase "( ~5° C)" reads -- (~5° C) --.

In column 93, line 60, a tilde should appear in place of the overline symbol so that the number “ $\overline{7}$ ” reads --  $\sim 7$ --.

In column 94, line 10, the fragment “ether” should read -- ethyl --.

In column 94, line 42, the term “gm” should read -- mg --.

In column 96, line 59, a comma should appear in place of the third period so that the phrase “mmol). (S)” reads -- mmol), (S)--.

In column 97, line 57, the fragment “benzioxzol” should read -- benzisoxazol --.

In column 99, line 5, the term “wash” should read -- was --.

In column 99, line 13, the number “<sub>25</sub>” should read -- <sub>23</sub> --.

In column 100, line 35, the number “<sub>25</sub>” should read -- <sub>23</sub> --.

In column 101, line 46, a tilde should appear in place of the overline symbol so that the phrase “ $\overline{50}^{\circ}$  C ” reads --  $\sim 50^{\circ}$  C --.

In column 103, line 35, the phrase “(4.72 g, 0.03 mole)” should read -- (4.72 g, 0.02 mole), potassium carbonate (4.14 g, 0.03 mole) --.

In column 104, line 48 to 49, a hyphen should appear in the fragment “4methylphthalic” so that it reads -- 4methylphthalic --.

In column 104, line 50, a period should appear in place of a comma in the term “1,0” so that it reads -- 1.0 --.

In column 104, line 51, a comma should appear in the phrase “(DCM 100 ml)” so that it reads -- (DCM, 100 ml) --.

In column 104, line 53, the term “at” should read -- a --.

In column 104, line 54, the term “SiO<sub>3</sub>” should read -- SiO<sub>2</sub> --.

In column 104, line 57, the closed bracket symbol should not appear.

In column 104, line 59, the fragment “O<sub>2</sub>” should read -- O<sub>3</sub> --.

In column 104, line 63, the fragment “1.2” should read -- 1,2 --.

In column 104, line 64, the fragment “piperidiny]-4-” should read -- piperidiny]ethyl]-4- --.

In column 104, last line, a comma should appear in place of the period in the phrase “(2.63g. 0.01 mole)” so that the phrase reads -- (2.63g, 0.01 mole) --.

In column 105, line 1, a comma should appear in place of the period in the phrase “(1.78 g. 0.01 mole)” so that the phrase reads -- (1.78 g, 0.01 mole) --.

In column 105, line 21, the fragment “ethyl” should read -- ethyl --.

In column 105, line 24, a comma should appear in place of the period in the fragment "1.2" so that the fragment reads -- 1,2 --.

In column 105, line 39, a period should appear in the number "236" so that the number reads -- 2.36 --.

In column 105, line 44, the number "59.4096" should read -- 59.40% --.

In column 105, line 45, a period should appear in the number "6,28" so that the number reads -- 6.28 --.

In column 105, line 49, the fragment "1.2" should read -- 1,2 --.

In column 105, line 51 the fragment "1.2" should read -- 1,2 --.

In column 105, line 53, a comma should appear in place of the second period so that the term "mmoles." reads -- mmoles, --.

In column 105, line 60, a comma should appear in place of the first period so that the phrase "(820 mg. 1.0 eq)" reads -- (820 mg, 1.0 eq) --.

In column 105, line 62, the closed bracket symbol should not appear.

In Claim 1, column 106, line 1, the term " $(C_3-C_{10})$ " should read --  $(C_3-C_{10})$  --.

In Claim 1, column 106, line 41, a symbol for a single bond should appear in the term " $-(CH_2)_5$ " so that the term reads --  $-(CH_2)_n-$  --.

In Claim 1, column 106, line 44, a symbol for a triple bond should appear in place of the symbol for a double bond in the term “ $-\text{CH}_2-\text{C}=\text{C}-\text{CH}_2-$ ,” so that the term reads --  $-\text{CH}_2-\text{C}\equiv\text{C}-\text{CH}_2-$ , --.

In Claim 1, column 106, line 45, the last symbol for a single bond in the term “ $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-$ ,” should not appear, so that the term reads --  $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-$ , --, as it appears in U.S. patent 5,658,911, column 104, line 47.

In Claim 1, column 106, line 47, a symbol for a triple bond should appear in place of the symbol for a double bond in the term “ $-\text{CH}_2-\text{C}=\text{C}-\text{CH}_2-\text{CH}_2-$ ,” so that it reads --  $-\text{CH}_2-\text{C}\equiv\text{C}-\text{CH}_2-\text{CH}_2-$ , --.

In Claim 1, column 106, line 60, the phrase “ $-\text{NO}_2$ ,  $-\text{NO}_2$ ,” should read --  $-\text{NO}_2$ ,  $-\text{NH}_2$ , --.

In Claim 1, column 106, line 63, the phrase “mono a dialkylamino,” should read -- mono or dialkylamino, --.

In Claim 1, column 107, line 3, the fragment “alkyl,;” should read -- alkyl[,]; --.

In Claim 1, column 107, line 30, the term “ $-\text{NRF}_{10}$ ” should read --  $-\text{NHR}_{10}$  --.

In Claim 8, column 107, line 54, the term “is” as read -- in --.

In Claim 8, column 107, line 57, the fragment “ $\text{R}_3$ ” should read --  $\text{R}_2$  --.

MAR - 2 2007

In Claim 9, column 107, line 63, a comma should appear after the term "I", so that the term reads -- I, --.

In Claim 9, column 107, line 64, a symbol for a single bond should appear in the term "OCF<sub>3</sub>" so that the term reads -- -OCF<sub>3</sub> --.

In Claim 10, column 107, line 67, the term "5-position" should read -- 6-position --.

In Claim 13, column 108, line 3, the term "is" should read -- in --.

In Claim 15, column 108, line 9, the fragment "butoxy[" should read -- butoxy] --.

In Claim 16, column 108, line 12, an open bracket symbol should appear in place of an open parenthesis symbol in the fragment "1-[4-(3-" so that the fragment reads -- 1-[4-[3- --.

In Claim 16, column 108, line 14, the term "it" should read -- a --.

In Claim 23, column 108, line 41, an open bracket symbol should appear in place of the open parenthesis symbol in the fragment "(4-" so that the fragment reads -- [4- --.

In Claim 23, column 108, line 41, the fragment "ethoxy)" should read -- ethoxy] --.

In Claim 24, column 108, line 45, a hyphen should appear in the fragment "1 piperaziny]" so that it reads -- 1-piperaziny] --.

In Claim 25, column 109, line 27, the term "aryl" should read -- acyl --.

In Claim 26, column 109, line 47, a semicolon should appear at the end of the line, so that the phrase "wherein X is -O-" reads --wherein X is -O-; --.


In Claim 26, column 109, line 63, the phrase "*wherein Y is hydrogen,*" should read -- *wherein Y is hydrogen, and R is hydrogen,* --.

In Claim 27, column 110, line 25, the term "aryl" should read "acyl".

In Claim 28, column 110, line 51, a numeral one should appear in place of the numeral two, so that the phrase "F[, when p is 2;]" reads -- F[, when p is 1;] --.

In Claim 29, column 111, line 23, the first comma should not appear so that the phrase "aryl, lower alkyl," reads -- aryl, lower alkyl,--.

In Claim 29, column 111, line 28, the semicolon should appear after the chemical structure and not as a part of the structure so that the structure



In Claim 30, column 112, line 1, the phrase "-S-, or" should read -- -S-, -NH-, or --.

In Claim 30, column 112, line 22, a fragment "C=" should appear in the term

"-CH<sub>2</sub>-CH-CH<sub>2</sub>-" so that the term reads -- -CH<sub>2</sub>-C=CH-CH<sub>2</sub>-, --, as it appears in U.S. patent 5,658,911, column 110, line 30.

In Claim 30, column 112, line 23, a symbol for triple bond should appear in place of a symbol for a double bond in the term "-CH<sub>2</sub>-C=CH-CH<sub>2</sub>-" so that the term reads -- -CH<sub>2</sub>-C≡C-CH<sub>2</sub>-, --.

In Claim 30, column 112, line 24, a subscript "2", and an additional fragment "CH<sub>2</sub>" without a terminal symbol for a single bond should appear in the term "-CH<sub>2</sub>-CH=CH<sub>2</sub>-CH<sub>2</sub>-" so that it reads -- -CH<sub>2</sub>-CH=CH-CH<sub>2</sub>-CH<sub>2</sub>-, --, as it appears in U.S. patent 5,658,911, column 110, line 32.

In Claim 30, column 112, line 26, a symbol for a triple bond should appear in place of the symbol for a double bond in the term "-CH<sub>2</sub>-C=C-CH<sub>2</sub>-CH<sub>2</sub>-" so that the term reads -- -CH<sub>2</sub>-C≡C-CH<sub>2</sub>-CH<sub>2</sub>-, --.


In Claim 30, column 112, line 27, a symbol for a triple bond should appear in place of the symbol for a double bond, and the last symbol for a single bond should not appear in the term "-CH<sub>2</sub>-CH<sub>2</sub>-C=C-CH<sub>2</sub>-" so that the term reads -- -CH<sub>2</sub>-CH<sub>2</sub>-C≡C-CH<sub>2</sub>-, -- as it appears in U.S. patent 5,658,911, column 110, line 35.

In Claim 30, column 112, line 30, an extra digit should not appear, so that the phrase "R<sub>22 1</sub> is R<sub>20</sub>" reads -- R<sub>22</sub> is R<sub>20</sub> --, as it appears in U.S. patent 5,658,911, column 110, line 37.

In Claim 30, column 112, line 53, the fragment "(OR<sub>2</sub>)" should read -- (OR<sub>7</sub>) --.



In Claim 30, column 112, line 60, the semicolon should appear after the chemical structure and not as a part of the structure so that the structure



In Claim 30, column 113, line 8, a symbol for single bond should appear in the term “NH–,” so that it reads -- NH–, --.

In Claim 30, column 113, line 8, the term “–CH=K–,” should read -- –CH=N–; --.

In Claim 30, column 113, line 9, a symbol for a single bond should appear in place of the symbol for a double bond, and an additional symbol for a single bond appear in the term “–N=R<sub>9</sub>,” so that the should read -- N–R<sub>9</sub>;--.

In Claim 30, column 113, line 22, the term “C<sub>3</sub>” should read -- C<sub>4</sub> --.

In Claim 31, column 113, line 54, the term “R<sub>1</sub>” should read --R<sub>2</sub>--.

In Claim 31, column 113, line 55, a comma should appear after the second occurrence of “aryl”, so that the phrase “aryl (C<sub>3</sub>–C<sub>10</sub>)” reads -- aryl, (C<sub>3</sub>–C<sub>10</sub>) --.


In Claim 31, column 113, line 67, a symbol for triple bond should appear in place of a symbol for a double bond, and a “2” should appear in a subscript in the term “–CH<sub>2</sub>–C=C–CH<sub>2</sub>–,” so that the term reads -- –CH<sub>2</sub>–C≡C–CH<sub>2</sub>–, --.

In Claim 31, column 114, line 1, the last dash should not appear, so that the term “ $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-$ ,” reads --  $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-$ , --, as it appears in U.S. patent 5,658,911, column 112, line 32.

In Claim 31, column 114, line 3, a symbol for triple bond should appear in place of a symbol for a double bond in the term “ $-\text{CH}_2-\text{C}=\text{C}-\text{CH}_2-\text{CH}_2-$ ,” so that the term reads --  $-\text{CH}_2-\text{C}\equiv\text{C}-\text{CH}_2-\text{CH}_2-$ , --.

In Claim 31, column 114, line 4, a symbol for triple bond should appear in place of a symbol for a double bond and the last symbol for a single bond should not appear in the term “ $-\text{CH}_2-\text{CH}_2-\text{C}=\text{C}-\text{CH}_2-$ ,” so that the term reads --  $-\text{CH}_2-\text{CH}_2-\text{C}\equiv\text{C}-\text{CH}_2-$ , --, as it appears in U.S. patent 5,658,911, column 112, line 35.

In Claim 31, column 114, line 34, the semicolon should appear after the chemical structure and not as a part of the structure so that the structure



In Claim 31, column 114, line 40, the phrase “trifluoromethyl, trifluoromethoxy” should read -- trifluoromethyl, or trifluoromethoxy --.

In Claim 31, column 114, line 49, the term “ $\text{CH}_8$ ” should read --  $\text{CHR}_8$  --.

In Claim 32, column 115, line 34, the term “alky” should read -- alkyl --.

In Claim 32, column 115, line 42, a symbol for triple bond should appear in place of a symbol for a double bond, and a "2" should appear in a subscript in the term " $-\text{CH}_2-\text{C}=\text{C}-\text{CH}_2-$ " so that the term reads --  $-\text{CH}_2-\text{C}\equiv\text{C}-\text{CH}_2-$  --.

In Claim 32, column 115, line 43, the last symbol for a single bond should not appear in the term " $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-$ ," so that the term reads --  $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-$  --, as it appears in U.S. patent 5,658,911, column 114, line 32.

In Claim 32, column 115, line 45, a symbol for triple bond should appear in place of a symbol for a double bond in the term the term " $-\text{CH}_2-\text{C}=\text{C}-\text{CH}_2-\text{CH}_2-$ ," so that the term reads --  $-\text{CH}_2-\text{C}\equiv\text{C}-\text{CH}_2-\text{CH}_2-$  --.

In Claim 32, column 115, line 46, a symbol for triple bond should appear in place of a symbol for a double bond and the last symbol for a single bond should not appear in the term " $-\text{CH}_2-\text{CH}_2-\text{C}=\text{C}-\text{CH}_2-$ ," so that the term read --  $-\text{CH}_2-\text{CH}_2-\text{C}\equiv\text{C}-\text{CH}_2-$  --, as it appears in U.S. patent 5,658,911, column 114, line 35.

In Claim 32, column 115, line 49, the term "substitutes" should read -- substituted --.


In Claim 32, column 115, line 59, a symbol for a single bond should appear in the term " $\text{NO}_2$ " so that the term reads --  $-\text{NO}_2-$  --.

In Claim 32, column 115, line 67, the term " $-(=\text{O})\text{-alkyl}$ ," should read --  $-\text{C}(=\text{O})\text{-alkyl}$  --.

MAR - 2 2007

MAR - 2 2007

In Claim 32, column 116, line 7, the semicolon should appear after the chemical structure and not as a part of the structure so that the structure



In Claim 32, column 116, line 14, a comma should follow the term “cyano” so that the term reads -- cyano, --.

In Claim 32, column 116, line 22, an extra dash should not appear, so that the term “-N-R<sub>9</sub>,” reads -- N-R<sub>9</sub>; --.

In Claim 33, column 116, line 67, the term “sad” should read -- and --.

In Claim 33, column 117, line 7, the term “R<sub>7</sub>” should read -- R<sub>1</sub> --.

In Claim 33, column 117, line 11, a symbol for a triple bond should appear in place of a symbol for a double bond and a “2” should appear in a subscript in the term in the term “-CH<sub>2</sub>-C=C-CH<sub>2</sub>-” so that the terms reads -- -CH<sub>2</sub>-C≡C-CH<sub>2</sub>- --.

In Claim 33, column 117, line 12, the last symbol for a single bond should not appear in the term “-CH<sub>2</sub>-CH=CH-CH<sub>2</sub>-CH<sub>2</sub>-,” so that the term reads -- -CH<sub>2</sub>-CH=CH-CH<sub>2</sub>-CH<sub>2</sub>--, as it appears in U.S. patent 5,658,911, column 116, line 27.

In Claim 33, column 117, line 14, a symbol for triple bond should appear in place of a symbol for a double bond in the term the term “-CH<sub>2</sub>-C=C-CH<sub>2</sub>-CH<sub>2</sub>-,” so

that the term reads --  $\text{--CH}_2\text{--C}\equiv\text{C--CH}_2\text{--CH}_2\text{--}$ , --.

In Claim 33, column 117, line 15, a symbol for triple bond should appear in place of a symbol for a double bond and the last symbol for a single bond should not appear in the term " $\text{--CH}_2\text{--CH}_2\text{--C=C--CH}_2\text{--}$ ," so that the term read --  $\text{--CH}_2\text{--CH}_2\text{--C}\equiv\text{C--CH}_2\text{--}$ , --, as it appears in U.S. patent 5,658,911, column 116, line 30.

In Claim 33, column 117, line 27, a term "is" should appear in place of the first comma so that the phrase " $Z_1$ , lower" reads --  $Z_1$  is lower --.


In Claim 33, column 117, line 32, the term "at" should read -- or --.

In Claim 33, column 117, line 32, a comma should appear in the term "dialkylamino" so that the phrase reads as -- dialkylamino, --.

In Claim 33, column 117, line 32, a comma should not appear in the phrase "lower alkyl, thio," so that the phrase reads as -- lower alkyl thio, --.

In Claim 33, column 117, lines 34 to 35, a comma should appear in the phrase "monoalkylaminocarbonyl dialkylaminocarbonyl," so that the phrase reads as -- monoalkylaminocarbonyl, dialkylaminocarbonyl,--.

In Claim 33, column 117, line 44, the semicolon should appear after the chemical structure and not as a part of the structure so that the structure



In Claim 33, column 117, line 48, the term "Iodine," should read -- iodine, --.

In Claim 33, column 117, line 61, the term "alkonyl" should read -- alkanoyl --.

In Claim 33, column 117, line 67, the term "arc" should read -- are --.

In Claim 33, column 118, line 3, a comma should appear in the phrase  
"R is hydrogen" so that the phrase reads as -- R is hydrogen, --.

In Claim 33, column 118, line 6, the term " $R_7$ " should read --  $R_{23}$  --.

In Claim 33, column 118, line 9, which reads "[ $R_1$  is  $R_{20}$ ]  $m=1$ ;" should read  
-- [ $R_1$  is  $R_{20}$ ] R is H, and  $m=1$ ; --.

In Claim 38, column 118, line 35, the term "producer" should read -- produce --.

In Claim 39, column 118, line 40, the phrase "claimed in 1," should read  
-- claimed in claim 1, --.

In Claim 43, column 118, line 55, the phrase "claimed in 1." should read  
-- claimed in claim 1. --.

In Claim 45, column 118, line 65, the phrase "sulfuric add" should read  
-- sulfuric acid --

In Claim 46, column 119, line 19, a comma and a space should appear in the phrase  
“*aryl(C<sub>3</sub>-C<sub>10</sub>) cycloalkyl*,” so that the phrase reads  
-- *aryl, (C<sub>3</sub>-C<sub>10</sub>) cycloalkyl*, --.

In Claim 46, column 119, line 20, the term “*lkanoyl*” should read --*alkanoyl* --.

In Claim 46, column 119, line 22, a semicolon should appear in place of a colon, so  
that the phrase “2.” reads -- 2; --.

In Claim 46, column 119, line 23, the phrase “*Y hydrogen*” should read  
-- *Y is hydrogen* --.

In Claim 46, column 119, line 30, a symbol for a triple bond should appear in place of  
a symbol for a double bond, and the number “2” should appear as a subscript in  
the term “*-CH<sub>2</sub>-C=C-CH<sub>2</sub>-*,” so that the term reads -- *-CH<sub>2</sub>-C≡C-CH<sub>2</sub>-*, --.

In Claim 46, column 119, line 33, a symbol for a triple bond should appear in place of  
a symbol for a double bond in the term “*-CH<sub>2</sub>-C=C-CH<sub>2</sub>-CH<sub>2</sub>-*,” so that the  
term reads -- *-CH<sub>2</sub>-C≡C-CH<sub>2</sub>-CH<sub>2</sub>-*, --.

In Claim 46, column 119, line 34, a symbol for a triple bond should appear in place of  
a symbol for a double bond in the term “*-CH<sub>2</sub>-CH<sub>2</sub>-C=C-CH<sub>2</sub>-*,” should read  
-- *-CH<sub>2</sub>-CH<sub>2</sub>-C≡C-CH<sub>2</sub>-*, --.

In Claim 46, column 119, line 39, the term “*fluoromethyl*” should read  
-- *trifluoromethyl* --.

In Claim 46, column 119, line 41, the term “ $\text{--}(=\text{O})\text{-alkyl}$ ” should read

$\text{--}\text{--}\text{--}\text{C}(=\text{O})\text{-alkyl}\text{--}\text{--}$ .

In Claim 46, column 119, line 67, the phrase “*lower alkoxy*” should read  $\text{--}\text{--}\text{--}\text{alkoxy}\text{--}\text{--}$ .

In Claim 46, column 120, line 7, an extra comma should not appear in the phrase

“ $\text{C}_1\text{--C}_4$ , *alkyl*,” so that the phrase reads  $\text{--}\text{--}\text{--}\text{C}_1\text{--C}_4\text{ } *alkyl*, \text{--}\text{--}$ .

In Claim 46, column 120, a comma should appear immediately after the term “*iodine*”

so that the term reads  $\text{--}\text{--}\text{--}\text{iodine}, \text{--}\text{--}$ .

In Claim 46, column 120, line 13, an extra comma should not appear in the phrase

“*salt, thereof*.” so that the phrase reads  $\text{--}\text{--}\text{--}\text{salt thereof}\text{--}\text{--}$ .

In Claim 47, column 120, line 16, the phrase “ $\text{--O--}, \text{or --O--}$ ,” should read

$\text{--}\text{--}\text{--}\text{O--}, \text{or --S--}, \text{--}\text{--}$ .

In Claim 53, column 120, line 32, the phrase “*R is from*” should read

$\text{--}\text{--}\text{--}\text{R is selected from}\text{--}\text{--}$ .

In Claim 53, column 120, line 34, the phrase “*Br*,” should read  $\text{--}\text{--}\text{--}\text{Br}, \text{I}, \text{--}\text{--}$ .

In Claim 54, column 120, line 37, the term “*X*” should read  $\text{--}\text{--}\text{--}\text{Y}\text{--}\text{--}$ .

In Claim 62, column 120, line 60, the phrase “*salts mineral acids*,” should read

$\text{--}\text{--}\text{--}\text{salts of mineral acids}, \text{--}\text{--}$ .



In Claim 63, column 120, line 66, the phrase "*acetic is acid*" should read

-- *acetic acid* --.

In Claim 64, column 121, line 19, the phrase "*consisting lower*" should read

-- *consisting of lower* --.

In Claim 64, column 121, line 29, the phrase "*alkoxy, alkoxy hydroxy,*" should read

-- *alkoxy, hydroxy,* --.

In Claim 64, column 121, line 29, the phrase "*halogen p is*" should read

-- *halogen when p is* --.

In Claim 64, column 121, line 32, the term " $C_4$ " should read " $C_6$ ".

In Claim 64, column 121, line 44, which reads " $-NO_2$ , or *halogen*," should read

--  $-NO_2$ ,  $-NH_2$ , or *halogen, p as previously defined*; --.

In Claim 64, column 121, line 48, the term " $-CH_2-C=C-CH_2-$ " should read

--  $-CH_2-C\equiv C-CH_2-$ , --.

In Claim 64, column 121, line 52, the term " $-CH_2-C=C-CH_2-CH_2-$ " should read

--  $-CH_2-C\equiv C-CH_2-CH_2-$ , --.

In Claim 64, column 121, line 53, the term " $-CH_2-CH_2-C=C-CH_2-$ " should read

--  $-CH_2-CH_2-C\equiv C-CH_2-$ , --.

In Claim 64, column 121, line 58, an extra comma should not appear in the phrase  
“*lower alkyl, thio*,” so that the phrase reads -- *lower alkyl thio*--.

In Claim 64, column 122, line 9, the term “*flourine*” should read -- *fluorine* --.

In Claim 64, column 122, line 10, a comma should appear after the term  
“*dialkylamino*” so that the term reads -- *dialkylamino*, --.

In Claim 64, column 122, lines 10 to 11, a comma should appear after the term  
“*trifluoromethyl*” so that the term reads -- *trifluoromethyl*, --.

In Claim 64, column 122, line 24, the phrase “*lower alkoxy*” should read -- *alkoxy* --.

In Claim 64, column 122, line 27, the phrase “*wherein and heteroaryl*” should read  
-- *wherein aryl and heteroaryl* --.

In Claim 64, column 122, line 32, the term “*C<sub>1</sub>C<sub>4</sub>*” should read -- *C<sub>1</sub>-C<sub>4</sub>* --.

In Claim 68, column 122, line 45, the term “*and*” should not appear.

In Claim 68, column 122, line 45 to 46, the phrase “*wherein n is 2, 3, or 4*.” should  
read -- *wherein X is -O-* --.

In Claim 71, column 122, line 52, the term “*-N(R<sub>2</sub>)*.” should read -- *-N(R<sub>2</sub>)*. --.

In Claim 72, column 122, line 55, the phrase “*C<sub>2</sub>-C<sub>3</sub>*” should read -- *C<sub>1</sub>-C<sub>3</sub>* --.

In Claim 72, column 122, line 57, the term “ $-NO_3$ ” should read --  $-NO_2$  --.

In Claim 79, column 123, lines 3 to 4, the phrase “*comprises a administering*” should read -- *comprises administering* --.

In Claim 80, column 123, line 8, a comma should appear immediately after the term “*effect*” so that the term reads -- *effect*, --.

In Claim 82, column 123, line 15, the phrase “*carboxylic is acids*” should read -- *carboxylic acids* --.

In Claim 84, column 123, line 44, the phrase “*aryl is defined hereinafter;*” should read -- *aryl is as defined hereinafter;* --.

In Claim 84, column 123, line 45, the phrase “*p is 2;*” should read -- *p is 1 or 2;* --.

In Claim 84, column 123, line 46, a comma should appear immediately after the phrase “*lower alkyl*”.

In Claim 84, column 123, line 47, a comma should appear immediately after the term “*iodine*”.

In Claim 84, column 123, line 53, the term “ $-CH_2-C=C-CH_2-$ ” should read --  $-CH_2-C\equiv C-CH_2-$ , --.

In Claim 84, column 123, line 56, the term “ $-CH_2-C=C-CH_2-CH_2-$ ” should read --  $-CH_2-C\equiv C-CH_2-CH_2-$ , --.

In Claim 84, column 123, line 57, the term " $-CH_2-CH_2-C=C-CH_2-$ ," should read  
--  $-CH_2-CH_2-C\equiv C-CH_2-$ , --.

In Claim 84, column 123, line 61, an extra comma should not appear in the phrase  
"*lower alkyl, thio,*" so that the phrase reads -- *lower alkyl thio*,--.

In Claim 84, column 123, line 63, a comma should appear immediately after the term  
"*dialkylaminocarbonyl*".

In Claim 84, column 124, line 5, a semicolon should appear immediately after the  
chemical structure.

In Claim 84, column 124, line 10, the phrase "*chlorine, bromine,*" should read  
-- *chlorine, fluorine, bromine,* --

In Claim 84, column 124, lines 11 to 12, the term "*or*" should appear between the last  
and next to last members of the definition of  $R_5$ , so that the phrase  
"*trifluoromethyl, trifluoromethoxy,*" reads  
-- *trifluoromethyl, or trifluoromethoxy,* --.

In Claim 84, column 124, line 33, the extra comma should not appear immediately  
after the term " $C_1-C_4$ ".

In Claim 84, column 124, line 34, a comma appear immediately after the term  
"*iodine*".

In Claim 85, column 124, line 39, the term "*pharmaceutically*" should read  
-- *pharmaceutical* --.

In Claim 85, column 124, line 58, the subscript "3" should read --2--, so that the  
phrase "*R<sub>3</sub> is selected*" reads -- *R<sub>2</sub> is selected* --.

In Claim 85, column 124, line 60, characters "--" and "C" should not be subscripted, so  
that the term "*(C<sub>2-C11</sub>)*" reads -- *(C<sub>2</sub>-C<sub>11</sub>)* --.

In Claim 85, column 124, line 61, the phrase "*aryl is defined hereinafter;*" should read  
-- *aryl is as defined hereinafter;* --.

In Claim 85, column 124, line 63, the term "*bromine,*" should appear immediately  
after the term -- *fluorine,* --.

In Claim 85, column 124, line 64, the second occurrence of the term "*hydroxy,*" in the  
first definition of Y should be deleted, and the term -- *nitro,* -- should appear in  
its place.

In Claim 85, column 125, line 1, the term "*s*" should read -- *is* --.

In Claim 85, column 125, line 10, which reads "*--NO<sub>2</sub>, or halogen,*" should read  
-- *--NO<sub>2</sub>, --NH<sub>2</sub>, or halogen, p as previously defined;* --.

In Claim 85, column 125, line 15, a symbol for a triple bond should appear in place of  
a symbol for a double bond in the term "*--CH<sub>2</sub>-C=C-CH<sub>2</sub>-*," so that the term  
reads -- *--CH<sub>2</sub>-C≡C-CH<sub>2</sub>-*, --.

In Claim 85, column 125, line 18, a symbol for a triple bond should appear in place of a symbol for a double bond in the term “ $-CH_2-C=C-CH_2-CH_2-$ ,” so that the term reads --  $-CH_2-C\equiv C-CH_2-CH_2-$ , --.

In Claim 85, column 125, line 19, a symbol for a triple bond should appear in place of a symbol for a double bond in the term “ $-CH_2-CH_2-C=C-CH_2-$ ,” so that the term reads --  $-CH_2-CH_2-C\equiv C-CH_2-$ , --.

In Claim 85, column 125, line 23, an extra comma should not appear in the phrase “*lower alkyl, thio,*” so that the phrase reads -- *lower alkyl thio,*--.

In Claim 85, column 125, line 35, a semicolon should appear immediately after the chemical structure.

In Claim 85, column 125, line 39, the term “*flourine*” should read -- *fluorine* --.

In Claim 85, column 125, line 41, the phrase “*trifluoromethyl, trifluoromethoxy;*” should read -- *trifluoromethyl, or trifluoromethoxy;* --.

In Claim 85, column 125, line 53, the phrase “*lower alkoxy*” should read -- *alkoxy* --.

In Claim 85, column 125, line 56, the phrase “*where and heteroaryl*” should read -- *wherein aryl and heteroaryl* --.

In Claim 85, column 125, line 60, the term “ $C_1C_4$ ” should read --  $C_1-C_4$  --.

In Claim 85, column 125, line 61, the phrase " $R_{23}$  is  $C_1$ - $C_4$  alkyl;" should read

--  $R_{23}$  is  $H$  or  $C_1$ - $C_4$  alkyl; --

In Claim 86, column 126, line 22, the phrase "*aryl is defined hereinafter;*" should read

-- *aryl is as defined hereinafter;* --.

In Claim 86, column 126, line 31, a symbol for a triple bond should appear in place of a symbol for a double bond, and the number "2" should appear subscripted in the term " $-CH_2-C=C-CH_2-$ ," so that the term reads --  $-CH_2-C\equiv C-CH_2-$ , --.

In Claim 86, column 126, line 34, a symbol for a triple bond should appear in place of a symbol for a double bond in the term " $-CH_2-C=C-CH_2-CH_2-$ ," so that the term reads --  $-CH_2-C\equiv C-CH_2-CH_2-$ , --.

In Claim 86, column 126, line 35, a symbol for a triple bond should appear in place of a symbol for a double bond in the term " $-CH_2-CH_2-C=C-CH_2-$ ," so that the term reads --  $-CH_2-CH_2-C\equiv C-CH_2-$ , --.

In Claim 86, column 126, line 39, the term "13" should not appear.

In Claim 86, column 126, line 50, a semicolon should appear immediately after the chemical structure.

In Claim 86, column 126, line 56, the phrase "*trifluoromethyl, trifluoromethoxy;*" should read -- *trifluoromethyl, or trifluoromethoxy;* --.

In Claim 86, column 127, line 2, the phrase "*lower alkoxy*" should read -- *alkoxy* --.

In Claim 86, column 127, line 10, the phrase " $R_{23}$  is  $C_1-C_4$  alkyl," should read

--  $R_{23}$  is H or  $C_1-C_4$  alkyl; --

In Claim 87, column 127, line 36, the phrase "*aryl is defined hereinafter*," should read

-- *aryl is as defined hereinafter*; --.

In Claim 87, column 127, line 44, the subscripted "4" should read as --6--, so that the phrase " $C_1-C_4$ " reads as --  $C_1-C_6$  --.

In Claim 87, column 127, line 53, which reads " $-NO_2$ , or halogen," should read

--  $-NO_2$ ,  $-NH_2$ , or halogen, *p* as previously defined; --.

In Claim 87, column 127, line 55, which reads " $R_1$ " should read --  $R_{21}$  --.

In Claim 87, column 127, line 57, a symbol for a triple bond should appear in place of a symbol for a double bond and the last number "2" should appear subscripted in the term " $-CH_2-C=C-CH_2-$ ," so that the term reads

--  $-CH_2-C\equiv C-CH_2-$ , --.

In Claim 87, column 127, line 60, a symbol for a triple bond should appear in place of a symbol for a double bond in the term " $-CH_2-C=C-CH_2-CH_2-$ ," so that the term reads --  $-CH_2-C\equiv C-CH_2-CH_2-$ , --.

In Claim 87, column 127, line 61, a symbol for a triple bond should appear in place of a symbol for a double bond in the term " $-CH_2-CH_2-C=C-CH_2-$ ," so that the term reads --  $-CH_2-CH_2-C\equiv C-CH_2-$ , --.



In Claim 87, column 128, line 1, immediately in front of the term  
“*dialkylaminocarbonyl*” the term --*monoalkylaminocarbonyl*, -- should appear.

In Claim 87, column 128, line 3, the term “13” should not appear.

In Claim 87, column 128, line 4, a symbol for a single bond should appear in the term  
“C(=W)-aryl,” so that the term reads --C(=W)-aryl, --.

In Claim 87, column 128, line 10, a semicolon should appear immediately after the  
chemical structure.

In Claim 87, column 128, line 17, the phrase “*trifluoromethyl, trifluoromethoxy;*”  
should read -- *trifluoromethyl, or trifluoromethoxy;* --.

In Claim 87, column 128, line 36, a comma should appear after numeral “2”, so that  
the phrase “2 or 3” reads -- 2, or 3 --.

In Claim 87, column 128, line 40, the phrase “*R<sub>23</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl;*” should read  
-- *R<sub>23</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl;* --.

In Claim 90, column 129, line 10, the phrase “*aryl is defined hereinafter;*” should read  
-- *aryl is as defined hereinafter;* --.

In Claim 90, column 129, line 20, a symbol for a triple bond should appear in place of  
a symbol for a double bond in the term “-CH<sub>2</sub>-C=C-CH<sub>2</sub>-,” so that the term  
reads -- -CH<sub>2</sub>-C≡C-CH<sub>2</sub>-, --.

In Claim 90, column 129, line 23, a symbol for a triple bond should appear in place of a symbol for a double bond in the term “ $-CH_2-C=C-CH_2-CH_2-$ ,” so that the term reads --  $-CH_2-C\equiv C-CH_2-CH_2-$ , --.

In Claim 90, column 129, line 24, a symbol for a triple bond should appear in place of a symbol for a double bond in the term “ $-CH_2-CH_2-C=C-CH_2-$ ,” so that the term reads --  $-CH_2-CH_2-C\equiv C-CH_2-$ , --.

In Claim 90, column 129, line 37, the term “13” should not appear.

In Claim 90, column 129, line 38, a symbol for a single bond should appear in the term “C(=W)-aryl,” so that the term reads -- C(=W)-aryl, --.

In Claim 90, column 129, line 44, a semicolon should appear immediately after the chemical structure.

In Claim 90, column 129, line 51, the phrase “trifluoromethyl, trifluoromethoxy;” should read -- trifluoromethyl, or trifluoromethoxy; --.

In Claim 90, column 129, line 66, the term “aryl.” should read as  
-- aryl,  $-C(=O)-aryl$ , or  $-C(=O)-heteroaryl$ ,  
wherein aryl and heteroaryl are as defined above; and  
m is 1, 2, or 3;  
with the exclusion of compounds wherein X is O or S, Y is hydrogen, and R is  
hydrogen,  $C_1-C_4$  alkyl, chlorine, fluorine, bromine, iodine, cyano,  $C_1-C_4$   
alkoxy, or  $-COOR_{23}$  wherein  $R_{23}$  is H or  $C_1-C_4$  alkyl;

*all geometric, optical and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof, in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier therefor. --*

In Claim 91, column 130, line 22, the phrase “*aryl is defined*” should read  
-- *aryl is as defined* --.

In Claim 91, column 130, line 30, the term “ $C_4$ ” should read --  $C_6$  --.

In Claim 91, column 130, line 38, which reads “ $-NO_2$ , or halogen;” should read  
--  $-NO_2$ ,  $-NH_2$ , or halogen, *p* as previously defined; --.

In Claim 91, column 130, line 42, a symbol for a triple bond should appear in place of a symbol for a double bond the term “ $-CH_2-C=CH_2-$ ,” so that the term reads --  $-CH_2-C\equiv CH_2-$ , --.

In Claim 91, column 130, line 45, a symbol for a triple bond should appear in place of a symbol for a double bond the term “ $-CH_2-C=CH_2-CH_2-$ ,” so that the term reads --  $-CH_2-C\equiv CH_2-CH_2-$ , --.

In Claim 91, column 130, line 46, a symbol for a triple bond should appear in place of a symbol for a double bond the term “ $-CH_2-CH_2-C=CH_2-$ ,” so that the term reads --  $-CH_2-CH_2-C\equiv CH_2-$ , --.

In Claim 91, column 130, line 63, a semicolon should appear immediately after the chemical structure.

In Claim 91, column 131, line 2, the phrase “*trifluoromethyl, trifluoromethoxy;*” should read -- *trifluoromethyl, or trifluoromethoxy;* --.

In Claim 91, column 131, line 11, the phrase “*lower alkyl, or alkyl*” should read -- *lower alkyl, or lower alkyl-(C=O)-*; --.

In Claim 91, column 131, line 17, a comma should appear after numeral “2”, so that the phrase “*2 or 3*” reads -- *2, or 3* --.

In Claim 91, column 131, line 21, the phrase “*R<sub>23</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl;*” should read -- *R<sub>23</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl;* --.

In Claim 91, column 131, lines 26 to 27, the phrase “*an antipsychotic effect*” should read -- *a pain-relieving effect* --.

In Claim 94, column 131, line 52, the phrase “*consisting lower*” should read -- *consisting of lower* --.

In Claim 94, column 131, line 60, the second instance of “*alkoxy*” should not appear.

In Claim 94, column 131, line 62, the phrase “*n is 2, 3, or 5;*” should read -- *n is 2, 3, 4, or 5;* --.

In Claim 94, column 131, line 65, an extra comma should not appear in the phrase “*lower alkyl, thio,*” so that the phrase reads -- *lower alkyl thio,*--.

In Claim 94, column 131, line 67, immediately after the term “*aminocarbonyl*” the

term --*monoalkylaminocarbonyl*-- should appear.

In Claim 94, column 131, line 67, to column 132, line 1, immediately after the term "*dialkylaminocarbonyl*" a comma should appear.

In Claim 94, column 132, line 3, a comma should appear in place of a semicolon in the fragment "*alkyl*;" so that the fragment reads -- *alkyl*, --.

In Claim 94, column 132, line 7, a semicolon should appear immediately after the chemical structure.

In Claim 94, column 132, line 13, the term "*flourine*" should read -- *fluorine* --.

In Claim 94, column 132, line 31, the phrase "*m is 1, 2, or 3*," should be followed immediately by the phrase -- *with the proviso that at least one R is selected from the group consisting of dialkylaminocarbonyl, formyl, -C(=W)-aryl, and -C(=W)-heteroaryl*; --.

In Claim 94, column 132, line 34, the phrase "*R<sub>23</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl*;" should read -- *R<sub>23</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl*; --

In Claim 94, column 132, line 35, the superfluous line "*where R<sub>23</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl*;" should be deleted in its entirety.

In Claim 94, column 132, line 36, the phrase "--*S-*, *R*" should read -- *-S-*, *R<sub>1</sub> is R<sub>20</sub>*, *R* --.

In Claim 94, column 132, line 40, the term "*thereof*." should read

*-- thereof, in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier therefor. --.*

In Claim 95, column 132, line 42, the term “or” and a symbol for a single bond should appear in the phrase “ $-S-$ ,  $-NH-$ ” so that the phrase reads  
*--  $-S-$ , or  $-NH-$ . --.*

In Claim 102, column 132, line 59, the phrase “wherein is” should read  
*-- wherein X is --.*

In Claim 102, column 132, line 61, a comma should appear after the phrase  
“hydrogen  $C_1-C_3$ ” so that the phrase reads *-- hydrogen,  $C_1-C_3$  --.*

In Claim 102, column 132, line 63, the phrase “or  $-CF_3-$ ” should read *-- and  $-CF_3-$  --.*

In Claim 108, column 133, line 8, the phrase “effect, a” should read *-- effect, and a --.*

In Claim 109, column 133, line 11, the term “ministering” should read  
*-- administering --.*

In Claim 109, column 133, line 11, the term “amount” should read  
*-- effective amount --.*

In Claim 112, column 134, line 6, the phrase “salts of acids,” should read  
*-- salts of mineral acids, --.*

In Claim 112, column 134, line 6, the term “slats” should read *-- salts --.*

In Claim 113, column 134, line 12, the phrase "*group of salts*" should read

-- *group consisting of salts* --.

In Claim 113, column 134, line 13, a comma should appear in the phrase "*acetic acid propionic acid*," so that the phrase reads -- *acetic acid, propionic acid*, --.

**Remarks**

The patent owner requests that a corrected patent for U.S. Patent No. RE39,265 be issued under 37 C.F.R. § 1.322(b) in lieu of the issuance of a Certificate of Correction.

Section 1.322(b) of 37 C.F.R. states the following:

If the nature of the mistake on the part of the Office is such that a certificate of correction is deemed inappropriate in form, the Director may issue a corrected patent in lieu thereof as a more appropriate form for certificate of correction, without expense to the patentee.

The patent owner believes that the large number of errors and the substantive nature of the errors in the printed and electronic versions of the patent are such that a Certificate of Correction would be deemed inappropriate form of correcting the patent. The errors include errors that are based on omitted pages from the claims, extra paragraphs of text in claims, and substantive typographical errors. A Certificate of Correction submitted on Form PTO-1050 to amend all of the errors would be considerably longer than the patent itself.

All of the errors identified in the "Listing of Errors", as set forth above, are Patent Office mistakes. The errors in the present reissued patent (reissued September 5, 2006) include errors vis-à-vis the following documents:

- (A) Examiner's Amendment accompanying the Notice of Allowance dated November 8, 2005;
- (B) Reply dated May 18, 2005, filed in response to Examiner's Action dated January 21, 2005;
- (C) Reply dated November 3, 2004, filed in response to Examiner's Action dated June 3, 2004;




- (D) Reply dated February 12, 2004, filed in response to Examiner's Action dated November 12, 2003;
- (E) Reply dated August 27, 2003, filed in response to Examiner's Action dated May 27, 2003;
- (F) Reply dated February 28, 2003, filed in response to Examiner's Action dated August 30, 2002;
- (G) Reply dated June 13, 2002, filed in response to Examiner's Action dated December 14, 2001;
- (H) the text of Preliminary Amendment and Application No. 09/708,475, filed November 9, 2000; which issued as the present reissue patent;
- (I) U.S. Patent No. 5,658,911, issued August 19, 1997;

Corrections of the errors would not constitute new matter or require re-examination.

In view of the foregoing, the patent owner requests respectfully issuance of a corrected patent of Reissue Patent No. RE39,198. The Commissioner is authorized hereby to charge any fees associated with this Petition to Deposit Account No. 19-5425.

Respectfully submitted,



Peter D. Mlynek, Ph.D.  
Reg. No. 47,802  
Synnestvedt & Lechner LLP  
1101 Market Street  
Suite 2600  
Philadelphia, PA 19107-2950  
Telephone: 215-923-4466  
Facsimile: 215-923-2189